Georgia Marquez-Grap,Andrea Leung,Allison Kranyak et al.
Georgia Marquez-Grap et al.
Background: There have been significant advances in psoriatic disease research in recent years, leading to better understanding of genes involved and increased treatment options. Purpose: To guide current research priorities for psoriatic d...
Gaps in Documentation of Psoriatic Domains in General Rheumatologic Practices Compared to Rheumatology-Dermatology Combined Clinics [0.03%]
与风湿-皮肤联合诊所相比，一般风湿门诊中银屑病域文档记录的差距
Alexandra Lauren Rice,Sarah Gillespie,Nikhil Sai et al.
Alexandra Lauren Rice et al.
Background: In order to apply current treatment recommendations for psoriatic arthritis (PsA), a complete assessment of psoriatic disease domains must be completed by the clinician. This includes a musculoskeletal examina...
Understanding Psoriasis Patient Preferences for Biologic Dosing Frequencies: Insights From a Patient Survey [0.03%]
银屑病患者对生物制剂给药频率偏好的调查研究
Omar Alani,Carrington Webb,Nashwah Memon et al.
Omar Alani et al.
Biologic dosing frequency is a key concern among psoriasis (PsO) patients and physicians, yet dosing optimization remains a challenge. This study evaluates patient dosing preferences for IL-17 and IL-23 inhibitors, risankizumab (RZB) every ...
Bárbara Agustina Hernández,Paula Carolina Luna,Cristina Echeverria et al.
Bárbara Agustina Hernández et al.
Importance: Dengue infection is an emerging global health concern. Understanding its impact on patients with a history of psoriasis is essential, particularly concerning its potential to trigger psoriasis flare-ups. Addit...
All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis [0.03%]
泛发性脓疱病(GPP)的全因死亡率高于银屑病和普通人群：基于美国保险理赔资料分析
Alice B Gottlieb,Hannah Crooke Kwiatkowski,Juan Semeco et al.
Alice B Gottlieb et al.
Background: Limited literature exists on the mortality burden of generalized pustular psoriasis (GPP) in the US. Objective: To compare ...
Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network [0.03%]
银屑病与银屑病关节炎心血管风险评估实用建议：皮科、风湿免疫科及全科推荐方案（由银屑病和银屑病关节炎门诊多中心推进组织提出）
Samip Sheth,Karla Inestroza,Joseph F Merola et al.
Samip Sheth et al.
Patients with psoriasis (PsO) and psoriatic arthritis (PsA) are at significantly increased risk for cardiovascular (CV) disease, attributed to chronic systemic inflammation and a high burden of cardiometabolic comorbidities. Despite this, C...
Combining Clinical, Genetic and Protein Markers Using Machine Learning Models Discriminates Psoriatic Arthritis Patients From Those With Psoriasis [0.03%]
利用机器学习模型结合临床、遗传和蛋白质标志物鉴别银屑病关节炎患者和仅有银屑病的患者
Darshini Ganatra,Max Kotlyar,Amanda Dohey et al.
Darshini Ganatra et al.
Background: Psoriatic Arthritis (PsA), an immune mediated inflammatory arthritis, affects a quarter of patients with cutaneous psoriasis, usually after psoriasis onset. Early diagnosis of PsA is challenging. A biomarker-b...
Evaluating the Association Between Systemic Treatments for Moderate to Severe Psoriasis and SARS-CoV-2 Infection Outcomes [0.03%]
评估银屑病系统性治疗与新冠病毒感染结局之间关联的影响因素及区域差异
Rini Desai,Mehrtash Hashemzadeh,Liliana Tong et al.
Rini Desai et al.
Moderate to severe psoriasis is often treated with systemic medications, including traditional therapies (eg, methotrexate, cyclosporine) and biologics (eg, TNF inhibitors, IL-17 and IL-23 inhibitors). These immunomodulating treatments rais...
Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study [0.03%]
Ixekizumab在银屑病关节炎中的留存率及影响治疗持久性的因素：一项意大利多中心研究的结果
Camilla Mazzanti,Marino Paroli,Gianluca Santoboni et al.
Camilla Mazzanti et al.
IXE (Ixekizumab) is a monoclonal antibody targeting interleukin-17A (IL17A) which has demonstrated significant efficacy and safety in the management of psoriatic arthritis (PsA) in randomized controlled trials (RCTs). However, available dat...
Trends in Psoriatic Arthritis Management From 1993 to 2019: Rise of Biologics and Decline of Oral Small Molecules [0.03%]
银屑病关节炎的治疗趋势：生物制剂崛起，口服小分子药物式微（1993至2019年）
Brad R Woodie,Sarayu Balachandar,Alan B Fleischer Jr
Brad R Woodie
Background: Traditional oral small molecule disease-modifying antirheumatic drugs (OSMs) have historically been the cornerstone of psoriatic arthritis (PsA) management. However, biologics have gained prominence due to the...